Suppr超能文献

预防抗菌药物耐药性的药物组合:各种相关性和规律及其验证,从而提出一些原则和初步方案

Drug Combinations to Prevent Antimicrobial Resistance: Various Correlations and Laws, and Their Verifications, Thus Proposing Some Principles and a Preliminary Scheme.

作者信息

Yi Houqin, Yuan Ganjun, Li Shimin, Xu Xuejie, Guan Yingying, Zhang Li, Yan Yu

机构信息

Biotechnological Engineering Center for Pharmaceutical Research and Development, Jiangxi Agricultural University, Nanchang 330045, China.

Laboratory of Natural Medicine and Microbiological Drug, College of Bioscience and Bioengineering, Jiangxi Agricultural University, Nanchang 330045, China.

出版信息

Antibiotics (Basel). 2022 Sep 20;11(10):1279. doi: 10.3390/antibiotics11101279.

Abstract

Antimicrobial resistance (AMR) has been a serious threat to human health, and combination therapy is proved to be an economic and effective strategy for fighting the resistance. However, the abuse of drug combinations conversely accelerates the spread of AMR. In our previous work, we concluded that the mutant selection indexes (SIs) of one agent against a specific bacterial strain are closely related to the proportions of two agents in a drug combination. To discover probable correlations, predictors and laws for further proposing feasible principles and schemes guiding the AMR-preventing practice, here, three aspects were further explored. First, the power function (y = axb, a > 0) correlation between the SI (y) of one agent and the ratio (x) of two agents in a drug combination was further established based on the mathematical and statistical analyses for those experimental data, and two rules a1 × MIC1 = a2 × MIC2 and b1 + b2 = −1 were discovered from both equations of y = a1xb1 and y = a2xb2 respectively for two agents in drug combinations. Simultaneously, it was found that one agent with larger MPC alone for drug combinations showed greater potency for narrowing itself MSW and preventing the resistance. Second, a new concept, mutation-preventing selection index (MPSI) was proposed and used for evaluating the mutation-preventing potency difference of two agents in drug combination; a positive correlation between the MPSI and the mutant prevention concentration (MPC) or minimal inhibitory concentration (MIC) was subsequently established. Inspired by this, the significantly positive correlation, contrary to previous reports, between the MIC and the corresponding MPC of antimicrobial agents against pathogenic bacteria was established using 181 data pairs reported. These results together for the above three aspects indicate that the MPCs in alone and combination are very important indexes for drug combinations to predict the mutation-preventing effects and the trajectories of collateral sensitivity, and while the MPC of an agent can be roughly calculated from its corresponding MIC. Subsequently, the former conclusion was further verified and improved via antibiotic exposure to 43 groups designed as different drug concentrations and various proportions. The results further proposed that the C/MPC for the agent with larger proportion in drug combinations can be considered as a predictor and is the key to judge whether the resistance and the collateral sensitivity occur to two agents. Based on these above correlations, laws, and their verification experiments, some principles were proposed, and a diagram of the mutation-preventing effects and the resistant trajectories for drug combinations with different concentrations and ratios of two agents was presented. Simultaneously, the reciprocal of MPC alone (1/MPC), proposed as the stress factors of two agents in drug combinations, together with their SI in combination, is the key to predict the mutation-preventing potency and control the trajectories of collateral sensitivity. Finally, a preliminary scheme for antimicrobial combinations preventing AMR was further proposed for subsequent improvement research and clinic popularization, based on the above analyses and discussion. Moreover, some similar conclusions were speculated for triple or multiple drug combinations.

摘要

抗菌药物耐药性(AMR)一直是对人类健康的严重威胁,联合治疗被证明是对抗耐药性的一种经济有效的策略。然而,药物组合的滥用反而加速了AMR的传播。在我们之前的工作中,我们得出结论,一种药物对特定细菌菌株的突变选择指数(SIs)与药物组合中两种药物的比例密切相关。为了发现可能的相关性、预测因素和规律,以便进一步提出指导AMR预防实践的可行原则和方案,在此,我们进一步探索了三个方面。首先,基于对那些实验数据的数学和统计分析,进一步建立了一种药物的SI(y)与药物组合中两种药物的比例(x)之间的幂函数(y = axb,a > 0)相关性,并且分别从y = a1xb1和y = a2xb2这两个方程中发现了药物组合中两种药物的两条规则a1 × MIC1 = a2 × MIC2和b1 + b2 = -1。同时,发现对于药物组合单独具有较大MPC的一种药物在缩小自身突变选择窗和预防耐药性方面表现出更大的效力。其次,提出了一个新概念,即突变预防选择指数(MPSI),并用于评估药物组合中两种药物的突变预防效力差异;随后建立了MPSI与突变预防浓度(MPC)或最低抑菌浓度(MIC)之间的正相关关系。受此启发,利用报道的181对数据建立了抗菌药物对病原菌的MIC与相应MPC之间与先前报道相反的显著正相关关系。上述三个方面的这些结果共同表明,单独和组合时的MPC是药物组合预测突变预防效果和协同敏感性轨迹的非常重要的指标,并且一种药物的MPC可以从其相应的MIC大致计算出来。随后,通过对设计为不同药物浓度和各种比例的43组进行抗生素暴露,进一步验证和改进了前一个结论。结果进一步表明,药物组合中比例较大的药物的C/MPC可以被视为一个预测因素,并且是判断两种药物是否会出现耐药性和协同敏感性的关键。基于上述相关性、规律及其验证实验,提出了一些原则,并给出了两种药物不同浓度和比例的药物组合的突变预防效果和耐药轨迹图。同时,单独MPC的倒数(1/MPC),作为药物组合中两种药物的应激因素,连同它们组合时的SI,是预测突变预防效力和控制协同敏感性轨迹的关键。最后,基于上述分析和讨论,进一步提出了抗菌药物组合预防AMR的初步方案,以供后续改进研究和临床推广。此外,对于三联或多联药物组合推测了一些类似的结论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0f9d/9598766/2e7594d6cf68/antibiotics-11-01279-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验